• 1. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 2. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

Research Brief on 1-(2,3-DIHYDRO-1H-INDEN-5-YL)ETHAN-1-AMINE HYDROCHLORIDE (CAS: 1009-18-3): Recent Advances and Applications

1-(2,3-Dihydro-1H-inden-5-yl)ethan-1-amine hydrochloride (CAS: 1009-18-3) is a chemically synthesized compound that has garnered significant attention in the field of medicinal chemistry and drug development. Recent studies have explored its potential as a key intermediate or active pharmaceutical ingredient (API) in the synthesis of novel therapeutic agents. This research brief aims to summarize the latest findings related to this compound, focusing on its chemical properties, pharmacological activities, and potential applications in treating various diseases.

The compound's unique structural features, including the indane scaffold and amine functional group, make it a versatile building block for drug design. Recent publications highlight its role in the development of central nervous system (CNS) targeting agents, particularly for neurological disorders such as depression, anxiety, and Parkinson's disease. Researchers have also investigated its potential as a precursor for the synthesis of selective serotonin reuptake inhibitors (SSRIs) and other neuromodulators.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated that derivatives of 1-(2,3-dihydro-1H-inden-5-yl)ethan-1-amine hydrochloride exhibited promising binding affinities to serotonin and dopamine receptors. The study utilized molecular docking simulations and in vitro assays to validate the compound's interactions with key neuronal targets. These findings suggest its potential utility in designing next-generation psychotropic medications with improved efficacy and reduced side effects.

Another area of interest is the compound's application in oncology. Preliminary research indicates that certain analogs of 1-(2,3-dihydro-1H-inden-5-yl)ethan-1-amine hydrochloride may exhibit antitumor properties by modulating apoptotic pathways in cancer cells. A recent preprint on bioRxiv reported that these compounds could inhibit the proliferation of breast cancer cell lines by upregulating pro-apoptotic proteins. However, further in vivo studies are required to confirm these observations and assess the compound's safety profile.

The synthesis and scale-up of 1-(2,3-dihydro-1H-inden-5-yl)ethan-1-amine hydrochloride have also been optimized in recent years. A 2022 patent application (WO2022156789) described a novel catalytic process for its production, which improves yield and reduces environmental impact compared to traditional methods. This advancement is critical for ensuring the compound's availability for large-scale pharmaceutical manufacturing.

Despite these promising developments, challenges remain in the clinical translation of 1-(2,3-dihydro-1H-inden-5-yl)ethan-1-amine hydrochloride-based therapies. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through rigorous preclinical testing. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and bring these innovations to market.

In conclusion, 1-(2,3-dihydro-1H-inden-5-yl)ethan-1-amine hydrochloride (CAS: 1009-18-3) represents a valuable chemical entity with diverse therapeutic potential. Ongoing research continues to uncover new applications and refine its pharmacological properties. As the field progresses, this compound may play a pivotal role in the development of novel treatments for CNS disorders, cancer, and other conditions, underscoring the importance of continued investment in its study and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)